{"ticker": {"uuid": "2470c8c6-decb-4a14-81d6-50c136c404c5", "symbol": "MAZE", "name": "Maze Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$MAZE stock is down 10% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVFJJUlhMa3lqM0pyTW93X0lPcnZTNU1CcXN3ZjlxcWhwc0t2czR0bTRjOTBLNktzVkJyQlp5SHNIOUR1NHhRY1JqM1ZuMXJCY3NFQ2d3dVRKb2Z5d1NIN0Vpci1yWHZnMDYxazBUN2stTnJITGhpOW42Y1FIUm5zZHYzV05zTUJvRDVSZUh3Z3RUQVdsSjJSanBoWEpIMmkxWFZR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T14:56:00+00:00", "published_display": "10 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Maze Therapeutics, Inc. Insider Trading Activity", "summary": "Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised stock options to acquire 14,609 shares and subsequently sold all of them in open market transactions on July 1, 2026. The sales were executed at weighted average prices of $29.8650 and $30.3369 per share under", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-ba58b0d1541e.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:40:00", "published_display": "03 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) CEO\u2019s family trusts sell 34,501 shares under 10b5-1 plan", "summary": "Family trusts associated with Maze Therapeutics (MAZE) CEO Jason V. Coloma sold a total of 34,501 shares of common stock on July 1, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, were reported at weighted average pric", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-e0f15e10bb73.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:39:26", "published_display": "02 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Maze Therapeutics, Inc. \u2013 NASDAQ:MAZE", "summary": "This article focuses on the enterprise value to EBITDA forward for Maze Therapeutics, Inc. (NASDAQ: MAZE). It appears to be a financial data page from TradingView, providing financial metrics and market information for the company. The content includes details like market status,", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T07:14:54", "published_display": "02 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise", "summary": "Maze Therapeutics, Inc. (NASDAQ: MAZE) has filed a Form 144 notice for the proposed sale of 46,892 common shares, scheduled for July 1, 2026, through the exercise of stock options with cash proceeds. The filing also reports two previous 10b5-1 sales by Harold Bernstein totaling 2", "url": "https://www.stocktitan.net/sec-filings/MAZE/144-maze-therapeutics-inc-sec-filing-438306c38a75.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:34", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares", "summary": "Atul Dandekar, CSBO at Maze Therapeutics (NASDAQ:MAZE), sold 7,500 shares for $210,150 on June 29, 2026, while simultaneously acquiring 7,500 shares through stock options for $78,150. These transactions were conducted under a Rule 10b5-1 trading plan. Following these moves, Dande", "url": "https://www.investing.com/news/insider-trading-news/maze-therapeutics-csbo-atul-dandekar-sells-210150-in-shares-93CH-4771506", "source_name": "Investing.com", "published_at": "2026-07-01T21:09:34", "published_display": "01 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAZE (MAZE) trusts sell tens of thousands of common shares May\u2013June 2026", "summary": "MAZE Therapeutics, Inc. (MAZE) reported through a Form 144 filing that related trusts, specifically the Coloma Family Trust and the Coloma 2021 Irrevocable Trust, sold common shares between May and June 2026. The filing details multiple transactions including share counts and sal", "url": "https://www.stocktitan.net/sec-filings/MAZE/144-maze-therapeutics-inc-sec-filing-86af23ba53e2.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:34", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan", "summary": "Maze Therapeutics CSBO Atul Dandekar exercised 7,500 stock options at $10.42 per share and subsequently sold 7,500 shares of common stock at $28.02 per share. These transactions, totaling $210,150, were conducted on June 29 under a pre-arranged Rule 10b5-1 trading plan. Following", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-099340f74e28.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:34", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Maze Therapeutics, Inc. \u2013 NASDAQ:MAZE", "summary": "This article provides a financial snapshot of Maze Therapeutics, Inc. (NASDAQ: MAZE), focusing on its forward price-to-earnings ratio. It indicates that no trades were made and the market is currently closed for the company. The content also lists various financial and analytical", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T02:39:54", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Maze Therapeutics, Inc. \u2013 NASDAQ:MAZE", "summary": "This page provides financial information for Maze Therapeutics, Inc. (NASDAQ: MAZE), focusing on its enterprise value to revenue forward. The content appears to be from TradingView, offering an overview of the company's financial data.", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T02:10:52", "published_display": "30 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Maze Therapeutics, Inc. \u2013 BOATS:MAZE", "summary": "This article provides financial information for Maze Therapeutics, Inc. (MAZE) on the TradingView platform. It specifically focuses on the company's \"Price to book forward\" metric. The content highlights the financial data provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/BOATS-MAZE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:52", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Maze Therapeutics, Inc. \u2013 BOATS:MAZE", "summary": "This page displays information regarding the Price to Sales Forward metric for Maze Therapeutics, Inc. (BOATS:MAZE) on the TradingView platform. It indicates that the market is currently closed with no trades. The core content shows a \"Period Value Change Change %\" section, likel", "url": "https://www.tradingview.com/symbols/BOATS-MAZE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:25", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In?", "summary": "Maze Therapeutics (MAZE) has seen a significant rebound, with its stock up 5.2% in the past day and 10.7% over the past week, despite being down 28.51% year to date. The company trades at a Price to Book (P/B) ratio of 4.6x, indicating a higher valuation than the broader US pharm", "url": "https://www.sahmcapital.com/news/content/maze-therapeutics-maze-rebounds-this-week-is-the-upside-already-priced-in-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-28T02:39:54", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAZE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast and analysis for Maze Therapeutics, Inc. (MAZE) stock, including current price, analyst ratings, price targets, historical performance, earnings data, and future revenue expectations. It also answers frequently asked questions about MAZE", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:15", "published_display": "27 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE)", "summary": "This article provides an analysis of Maze Therapeutics, Inc. (NASDAQ: MAZE) stock, covering current price, market capitalization, historical performance, and future forecasts from analysts. It highlights that MAZE stock has shown significant growth over the last year and includes", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:46", "published_display": "26 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan", "summary": "Maze Therapeutics CEO Jason V. Coloma indirectly sold 27,858 shares of common stock through family trusts at an average price of approximately $26 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-aa76c13410be.html", "source_name": "Stock Titan", "published_at": "2026-06-25T02:10:52", "published_display": "25 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Inc (MAZE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Maze Therapeutics Inc.'s (MAZE) dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock split events. The page also presents current stock performance d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-maze/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:14", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options", "summary": "Richard H. Scheller, a director at Maze Therapeutics, has been granted 18,000 stock options with an exercise price of $23.58 per share, expiring on June 7, 2036. This compensation-related grant will vest on the earlier of the company's 2027 annual stockholders meeting or June 8, ", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-b7f055b36584.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:09:53", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Lim receives 18,000 Maze (MAZE) options vesting by 2027", "summary": "Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.58 per share. These options will vest and become fully exercisable by the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, provided Lim continues hi", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-e4503fc9149d.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:09:53", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58", "summary": "Maze Therapeutics director Herve Hoppenot was granted 18,000 stock options with an exercise price of $23.58 per share. These options, granted on June 8, 2026, will vest fully on the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, contingent on his conti", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-c182c24ef781.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:09:53", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "18,000 Maze Therapeutics (MAZE) options granted to director Andrews", "summary": "Maze Therapeutics director Nancy C. Andrews was granted 18,000 stock options with an exercise price of $23.58 per share, expiring on June 7, 2036. The options will vest on the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, contingent on her continued s", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-6c59b86f8b3f.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:39:43", "published_display": "11 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWmpDV1JOVThYeFNXNzNVcW1TUWJJMWJDSkpKSWtCcTFfVFVZSHJwaU5OMmo0NmFKRG1PWnRQS2xJZ3RkZVdRVmlXQUU2SEhVMDlhLWZkWkZrUnRMMWlKTzh6cGs3eUdIeVU2Ry1mQWdIemswMnJrVFhicVZ3cHYwR0VBZUxiNk5qa2ZWa2l0a1RZNnVPbzIzWGdTcV8yVE9WSUlN?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxOYUNVZnRKcmJBVjlxTjh2SzFUTEdSUzVweG5fdUtySFBvVXpEOHIwWFYzZzBVRHJRUjRnY3VuR1lWVHhCUk9CU3lEVTlKRkZjVlFkT1pHbmRIZDkwN2lGdTh1cUw2eGlQczNqWkZSR2R6ZzRsVjI0MHlHZW5nbmlsNnU1SWN4aGxGczM0RVAyOWFRWVJTVG1FeW52anNsSUtSRjlxUjlxa005dHVzZzFKODc4RDlTZmp0SEtBYU5ZTFVxa0xMMlVlT05vTDE5NnFLamtPTnNDZGdia0VCNy1ieDdPTmNvTzFxS1Y4V1lWR3NWZw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNc3B4bHJPcHhZWmQ0NkZwQW9hZHV6VW5kODhidVJHaFg0UUYxOTNKM2pKVnQ5ZFZURjNnZHdRelo4S3FRTDcxTTZ1YmszQzRpZVFkVUtLNFhVWUdYLW9Ud0VZRzhvUGNvNXdqUEpoRldVMDNIbWdORkN1YkJFZ2ZielpaTU1jT1U?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nektar\u2019s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNX2J0NFZ4YWlmTjdvS0VGUEYwZ0hYZkNaS3U1NFRiQXNzUkptNk1rN1h6VGNVNlB3R0NkSDdBRTA4TUNhMERUcGhFZ1ZOZXRsZmxOcDFURTc5TFpYSTd3aktqTFoxX3I1V29aZzR3dUxoV2RlcVB2OUNOTmJjd2pTVTdXWEJ4dVZUWjVsa2djaDViRHVHSVBz?oc=5", "source_name": "Endpoints News", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross Proceeds | MAZE Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNSko5NG9reEg4WUVMeGVDc1g4M3Bhc0xQTVNiRzVJM3R0Z2RYMW9BMjh5WVhfTENQdFF4ZF84QkhlcW5LWEhfUTFIQ0Vwb25jcmFBd2JvaXZiNXl3aVUtNkhpbndueGx5Ry1LTlJzS2l3UHAwQ0tUVzFMUGtsVUo2cG8yS08tVU5kSnlxWGg1R0hWVjFjUkt1QVhyQzFsVURPdE50d092T3NmMlk5RVFUOEEyemNyZFljUVlYSk9SeGF4b21DeXl5VTdtOTA2OUVxc2tBVUtRV1ZGN0dWV2hNN1lXb20td3Z6d09uZU12WEJZejhtMmV2VGZR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOOUNaNnBIOHNnTG1NZW5PakxjZmk5VmctX0xlYi1fMmZHa1RPUXVRVWhOUDF2eGVNR1ZzcHZ0dVZXQTR2LUtRUTdYczQxeHZuX2dwOFlpZkp0djVLNlBxMTZxT2hUVTFyTVk5QS1sS0hwM056WVExSm1UcFNTcC1ob2QwUGljYnZfdkRTX0ZTdVg2dEpNRVVnYnFOakg4aEFIMGkzVU1ENFNxS2hyX01qWnRXNFRCQkViMjNDMlByWFQyWllJeEthSQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTnlSRms4S0dYNTlUbFFBNFk3SEl5QklkR0wwbTFUb01HM2ZDMlBKN1RwdTVoRFZGZDhpTGhIQU44bUdzOVFCS1JscUR5ODBHTkZnTlBOaUJkV3R0UlNCckdmaWdWTTVyWDNqZjh4SVhFa19pNmZjTmVERHpmVnFfOVZNSVJWcmd4eVJxRFptVFRDODJ6a0VsX2x5S3puQ3VIcEVpY0NZaUdxUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPVV9zN2d5WEVYaUQ1bkIydkJvOG9ZeHBkOGNrN29OQXZQeTFhbHY0cHNXTy0yQjF5am9RTFZBX1U3ek5XajctLThabk9MM01RV0I1a0pnTVl2Yk53OEFYeUpCcEpZOFRhM3AxVVV3ZDVieTkyNVlBNC1lNW1LUWktczFzREQ3b2R4b190eVdmYw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMFZSTTNRdXU5M2dzd0NpRVIzc18zaElPd0dQUngwZHN5SlRsV0FWRE9sd2Jka3RlX2psdlY5bmZtTHhYeVJJaHMzMUtQd21hblB3bmxFcmJkUEl5SmlPNGQ4cXF2MEFHemhIYXlpVmJhOG9jS1R1eEpoM1M3SHQ4OS16dzBzU1NmSnZvUmtpVHY3Q3ZfTUZyQkR0LVEtM1RFQ2NMUGpsVlR1Q2thWjNCZFVCU05kVDc1VW40SFNn?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPblB4NHU2VjBydGNzdmRDQ0FzcVAtX28ta1dLYVdUd2FQNDZ6V284SUhPY0dhRllKWUdIMktOYVNFN1dhcVdPOGxNSVBFZXEyc2hEcXo3Si0tLTdONEpRWFJ4czZLcjhUV08wN2hWWGgwZDJzOS1WN2pJeW1KSUhpdndxcFZXRi1mWlowcFZR?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wdEJ5RnpvZTdLUGxzaFZIN0lFeGk1QWhQbE1FOVBwTEFmOXZSWllYdlhoeGNUOE92U1d4SWFheGpfSU1veHVpWC1FQ1VwRXduTzZ3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T07:17:10+00:00", "published_display": "25 Apr 2025 07:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN Stock Price and Chart \u2014 NASDAQ:VRDN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5qWmxDUDN5VlBrWjVISWdmaVkxLTQ1UUYyYW1LYmdqbVpycS1lem5PR3g2bDd5cTRCYy1nQ0pzN0hMdEhSY0lWTVdaNmF2YWRGUF9WeFZZVE9ET2Vk?oc=5", "source_name": "TradingView", "published_at": "2022-12-21T08:00:00+00:00", "published_display": "21 Dec 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "$MAZE stock is down 10% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVFJJUlhMa3lqM0pyTW93X0lPcnZTNU1CcXN3ZjlxcWhwc0t2czR0bTRjOTBLNktzVkJyQlp5SHNIOUR1NHhRY1JqM1ZuMXJCY3NFQ2d3dVRKb2Z5d1NIN0Vpci1yWHZnMDYxazBUN2stTnJITGhpOW42Y1FIUm5zZHYzV05zTUJvRDVSZUh3Z3RUQVdsSjJSanBoWEpIMmkxWFZR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T14:56:00+00:00", "published_display": "10 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Maze Therapeutics, Inc. Insider Trading Activity", "summary": "Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised stock options to acquire 14,609 shares and subsequently sold all of them in open market transactions on July 1, 2026. The sales were executed at weighted average prices of $29.8650 and $30.3369 per share under", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-ba58b0d1541e.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:40:00", "published_display": "03 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) CEO\u2019s family trusts sell 34,501 shares under 10b5-1 plan", "summary": "Family trusts associated with Maze Therapeutics (MAZE) CEO Jason V. Coloma sold a total of 34,501 shares of common stock on July 1, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, were reported at weighted average pric", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-e0f15e10bb73.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:39:26", "published_display": "02 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Maze Therapeutics, Inc. \u2013 NASDAQ:MAZE", "summary": "This article focuses on the enterprise value to EBITDA forward for Maze Therapeutics, Inc. (NASDAQ: MAZE). It appears to be a financial data page from TradingView, providing financial metrics and market information for the company. The content includes details like market status,", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T07:14:54", "published_display": "02 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise", "summary": "Maze Therapeutics, Inc. (NASDAQ: MAZE) has filed a Form 144 notice for the proposed sale of 46,892 common shares, scheduled for July 1, 2026, through the exercise of stock options with cash proceeds. The filing also reports two previous 10b5-1 sales by Harold Bernstein totaling 2", "url": "https://www.stocktitan.net/sec-filings/MAZE/144-maze-therapeutics-inc-sec-filing-438306c38a75.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:09:34", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares", "summary": "Atul Dandekar, CSBO at Maze Therapeutics (NASDAQ:MAZE), sold 7,500 shares for $210,150 on June 29, 2026, while simultaneously acquiring 7,500 shares through stock options for $78,150. These transactions were conducted under a Rule 10b5-1 trading plan. Following these moves, Dande", "url": "https://www.investing.com/news/insider-trading-news/maze-therapeutics-csbo-atul-dandekar-sells-210150-in-shares-93CH-4771506", "source_name": "Investing.com", "published_at": "2026-07-01T21:09:34", "published_display": "01 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAZE (MAZE) trusts sell tens of thousands of common shares May\u2013June 2026", "summary": "MAZE Therapeutics, Inc. (MAZE) reported through a Form 144 filing that related trusts, specifically the Coloma Family Trust and the Coloma 2021 Irrevocable Trust, sold common shares between May and June 2026. The filing details multiple transactions including share counts and sal", "url": "https://www.stocktitan.net/sec-filings/MAZE/144-maze-therapeutics-inc-sec-filing-86af23ba53e2.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:34", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan", "summary": "Maze Therapeutics CSBO Atul Dandekar exercised 7,500 stock options at $10.42 per share and subsequently sold 7,500 shares of common stock at $28.02 per share. These transactions, totaling $210,150, were conducted on June 29 under a pre-arranged Rule 10b5-1 trading plan. Following", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-099340f74e28.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:34", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Maze Therapeutics, Inc. \u2013 NASDAQ:MAZE", "summary": "This article provides a financial snapshot of Maze Therapeutics, Inc. (NASDAQ: MAZE), focusing on its forward price-to-earnings ratio. It indicates that no trades were made and the market is currently closed for the company. The content also lists various financial and analytical", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T02:39:54", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Maze Therapeutics, Inc. \u2013 NASDAQ:MAZE", "summary": "This page provides financial information for Maze Therapeutics, Inc. (NASDAQ: MAZE), focusing on its enterprise value to revenue forward. The content appears to be from TradingView, offering an overview of the company's financial data.", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T02:10:52", "published_display": "30 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Maze Therapeutics, Inc. \u2013 BOATS:MAZE", "summary": "This article provides financial information for Maze Therapeutics, Inc. (MAZE) on the TradingView platform. It specifically focuses on the company's \"Price to book forward\" metric. The content highlights the financial data provided by ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/BOATS-MAZE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:52", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Maze Therapeutics, Inc. \u2013 BOATS:MAZE", "summary": "This page displays information regarding the Price to Sales Forward metric for Maze Therapeutics, Inc. (BOATS:MAZE) on the TradingView platform. It indicates that the market is currently closed with no trades. The core content shows a \"Period Value Change Change %\" section, likel", "url": "https://www.tradingview.com/symbols/BOATS-MAZE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:25", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In?", "summary": "Maze Therapeutics (MAZE) has seen a significant rebound, with its stock up 5.2% in the past day and 10.7% over the past week, despite being down 28.51% year to date. The company trades at a Price to Book (P/B) ratio of 4.6x, indicating a higher valuation than the broader US pharm", "url": "https://www.sahmcapital.com/news/content/maze-therapeutics-maze-rebounds-this-week-is-the-upside-already-priced-in-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-28T02:39:54", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAZE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast and analysis for Maze Therapeutics, Inc. (MAZE) stock, including current price, analyst ratings, price targets, historical performance, earnings data, and future revenue expectations. It also answers frequently asked questions about MAZE", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:15", "published_display": "27 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE)", "summary": "This article provides an analysis of Maze Therapeutics, Inc. (NASDAQ: MAZE) stock, covering current price, market capitalization, historical performance, and future forecasts from analysts. It highlights that MAZE stock has shown significant growth over the last year and includes", "url": "https://www.tradingview.com/symbols/NASDAQ-MAZE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:46", "published_display": "26 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan", "summary": "Maze Therapeutics CEO Jason V. Coloma indirectly sold 27,858 shares of common stock through family trusts at an average price of approximately $26 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-aa76c13410be.html", "source_name": "Stock Titan", "published_at": "2026-06-25T02:10:52", "published_display": "25 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Inc (MAZE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Maze Therapeutics Inc.'s (MAZE) dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock split events. The page also presents current stock performance d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-maze/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:14", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options", "summary": "Richard H. Scheller, a director at Maze Therapeutics, has been granted 18,000 stock options with an exercise price of $23.58 per share, expiring on June 7, 2036. This compensation-related grant will vest on the earlier of the company's 2027 annual stockholders meeting or June 8, ", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-b7f055b36584.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:09:53", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Lim receives 18,000 Maze (MAZE) options vesting by 2027", "summary": "Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.58 per share. These options will vest and become fully exercisable by the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, provided Lim continues hi", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-e4503fc9149d.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:09:53", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58", "summary": "Maze Therapeutics director Herve Hoppenot was granted 18,000 stock options with an exercise price of $23.58 per share. These options, granted on June 8, 2026, will vest fully on the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, contingent on his conti", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-c182c24ef781.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:09:53", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "18,000 Maze Therapeutics (MAZE) options granted to director Andrews", "summary": "Maze Therapeutics director Nancy C. Andrews was granted 18,000 stock options with an exercise price of $23.58 per share, expiring on June 7, 2036. The options will vest on the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, contingent on her continued s", "url": "https://www.stocktitan.net/sec-filings/MAZE/form-4-maze-therapeutics-inc-insider-trading-activity-6c59b86f8b3f.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:39:43", "published_display": "11 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWmpDV1JOVThYeFNXNzNVcW1TUWJJMWJDSkpKSWtCcTFfVFVZSHJwaU5OMmo0NmFKRG1PWnRQS2xJZ3RkZVdRVmlXQUU2SEhVMDlhLWZkWkZrUnRMMWlKTzh6cGs3eUdIeVU2Ry1mQWdIemswMnJrVFhicVZ3cHYwR0VBZUxiNk5qa2ZWa2l0a1RZNnVPbzIzWGdTcV8yVE9WSUlN?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxOYUNVZnRKcmJBVjlxTjh2SzFUTEdSUzVweG5fdUtySFBvVXpEOHIwWFYzZzBVRHJRUjRnY3VuR1lWVHhCUk9CU3lEVTlKRkZjVlFkT1pHbmRIZDkwN2lGdTh1cUw2eGlQczNqWkZSR2R6ZzRsVjI0MHlHZW5nbmlsNnU1SWN4aGxGczM0RVAyOWFRWVJTVG1FeW52anNsSUtSRjlxUjlxa005dHVzZzFKODc4RDlTZmp0SEtBYU5ZTFVxa0xMMlVlT05vTDE5NnFLamtPTnNDZGdia0VCNy1ieDdPTmNvTzFxS1Y4V1lWR3NWZw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNc3B4bHJPcHhZWmQ0NkZwQW9hZHV6VW5kODhidVJHaFg0UUYxOTNKM2pKVnQ5ZFZURjNnZHdRelo4S3FRTDcxTTZ1YmszQzRpZVFkVUtLNFhVWUdYLW9Ud0VZRzhvUGNvNXdqUEpoRldVMDNIbWdORkN1YkJFZ2ZielpaTU1jT1U?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nektar\u2019s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNX2J0NFZ4YWlmTjdvS0VGUEYwZ0hYZkNaS3U1NFRiQXNzUkptNk1rN1h6VGNVNlB3R0NkSDdBRTA4TUNhMERUcGhFZ1ZOZXRsZmxOcDFURTc5TFpYSTd3aktqTFoxX3I1V29aZzR3dUxoV2RlcVB2OUNOTmJjd2pTVTdXWEJ4dVZUWjVsa2djaDViRHVHSVBz?oc=5", "source_name": "Endpoints News", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross Proceeds | MAZE Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNSko5NG9reEg4WUVMeGVDc1g4M3Bhc0xQTVNiRzVJM3R0Z2RYMW9BMjh5WVhfTENQdFF4ZF84QkhlcW5LWEhfUTFIQ0Vwb25jcmFBd2JvaXZiNXl3aVUtNkhpbndueGx5Ry1LTlJzS2l3UHAwQ0tUVzFMUGtsVUo2cG8yS08tVU5kSnlxWGg1R0hWVjFjUkt1QVhyQzFsVURPdE50d092T3NmMlk5RVFUOEEyemNyZFljUVlYSk9SeGF4b21DeXl5VTdtOTA2OUVxc2tBVUtRV1ZGN0dWV2hNN1lXb20td3Z6d09uZU12WEJZejhtMmV2VGZR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOOUNaNnBIOHNnTG1NZW5PakxjZmk5VmctX0xlYi1fMmZHa1RPUXVRVWhOUDF2eGVNR1ZzcHZ0dVZXQTR2LUtRUTdYczQxeHZuX2dwOFlpZkp0djVLNlBxMTZxT2hUVTFyTVk5QS1sS0hwM056WVExSm1UcFNTcC1ob2QwUGljYnZfdkRTX0ZTdVg2dEpNRVVnYnFOakg4aEFIMGkzVU1ENFNxS2hyX01qWnRXNFRCQkViMjNDMlByWFQyWllJeEthSQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTnlSRms4S0dYNTlUbFFBNFk3SEl5QklkR0wwbTFUb01HM2ZDMlBKN1RwdTVoRFZGZDhpTGhIQU44bUdzOVFCS1JscUR5ODBHTkZnTlBOaUJkV3R0UlNCckdmaWdWTTVyWDNqZjh4SVhFa19pNmZjTmVERHpmVnFfOVZNSVJWcmd4eVJxRFptVFRDODJ6a0VsX2x5S3puQ3VIcEVpY0NZaUdxUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPVV9zN2d5WEVYaUQ1bkIydkJvOG9ZeHBkOGNrN29OQXZQeTFhbHY0cHNXTy0yQjF5am9RTFZBX1U3ek5XajctLThabk9MM01RV0I1a0pnTVl2Yk53OEFYeUpCcEpZOFRhM3AxVVV3ZDVieTkyNVlBNC1lNW1LUWktczFzREQ3b2R4b190eVdmYw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMFZSTTNRdXU5M2dzd0NpRVIzc18zaElPd0dQUngwZHN5SlRsV0FWRE9sd2Jka3RlX2psdlY5bmZtTHhYeVJJaHMzMUtQd21hblB3bmxFcmJkUEl5SmlPNGQ4cXF2MEFHemhIYXlpVmJhOG9jS1R1eEpoM1M3SHQ4OS16dzBzU1NmSnZvUmtpVHY3Q3ZfTUZyQkR0LVEtM1RFQ2NMUGpsVlR1Q2thWjNCZFVCU05kVDc1VW40SFNn?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPblB4NHU2VjBydGNzdmRDQ0FzcVAtX28ta1dLYVdUd2FQNDZ6V284SUhPY0dhRllKWUdIMktOYVNFN1dhcVdPOGxNSVBFZXEyc2hEcXo3Si0tLTdONEpRWFJ4czZLcjhUV08wN2hWWGgwZDJzOS1WN2pJeW1KSUhpdndxcFZXRi1mWlowcFZR?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics (MAZE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wdEJ5RnpvZTdLUGxzaFZIN0lFeGk1QWhQbE1FOVBwTEFmOXZSWllYdlhoeGNUOE92U1d4SWFheGpfSU1veHVpWC1FQ1VwRXduTzZ3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T07:17:10+00:00", "published_display": "25 Apr 2025 07:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN Stock Price and Chart \u2014 NASDAQ:VRDN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5qWmxDUDN5VlBrWjVISWdmaVkxLTQ1UUYyYW1LYmdqbVpycS1lem5PR3g2bDd5cTRCYy1nQ0pzN0hMdEhSY0lWTVdaNmF2YWRGUF9WeFZZVE9ET2Vk?oc=5", "source_name": "TradingView", "published_at": "2022-12-21T08:00:00+00:00", "published_display": "21 Dec 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 52, "sentiment_summary": {"positive": 8, "negative": 4, "neutral": 40, "score": 52, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.19, "count": 19}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 30.57, "latest_week": "2026-07-10", "one_week_move": -2.2, "four_week_move": 27.1, "twelve_week_move": 8.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.162577, "market_dynamics_buy_signal": false, "relative_strength": -15.201407, "fair_value_gap": 23.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.4066, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.2% over one week, +27.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 10}, {"label": "Quiver Quantitative", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "TIKR.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 19}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.2% over one week, +27.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "$MAZE stock is down 10% today. Here's what we see in our data."}], "updated_at": "2026-07-16T06:06:21.580856+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}